Belantamab Mafodotin, Pomalidomide, and Dexamethasone in Multiple Myeloma

In patients with relapsed or refractory myeloma, 1-year progression-free survival was 20 percentage points higher with belantamab mafodotin, pomalidomide, and dexamethasone than with bortezomib, pomalidomide, and dexamethasone.

​   The New England Journal of Medicine: Search Results in Hematology/Oncology